Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate (177)Lu-NNV003

PURPOSE: The aim of this study was to explore the β-emitting lutetium-177 labelled anti-CD37 antibody NNV003 ((177)Lu-NNV003, Humalutin®) for the treatment of non-Hodgkin’s lymphoma in in vitro studies and in animal models. METHODS: Cytotoxicity of (177)Lu-NNV003 was measured in REC-1 (mantle cell l...

Descripción completa

Detalles Bibliográficos
Autores principales: Maaland, Astri Fjelde, Heyerdahl, Helen, O’Shea, Adam, Eiriksdottir, Bergthora, Pascal, Véronique, Andersen, Jan Terje, Kolstad, Arne, Dahle, Jostein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717602/
https://www.ncbi.nlm.nih.gov/pubmed/31309259
http://dx.doi.org/10.1007/s00259-019-04417-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717602/
https://www.ncbi.nlm.nih.gov/pubmed/31309259
http://dx.doi.org/10.1007/s00259-019-04417-1

Ejemplares similares